Clinical Trial Detail

NCT ID NCT04009967
Title Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning (PICT-01)
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors CHU de Quebec-Universite Laval
Indications

prostate cancer

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.